Terlipressin therapy for renal failure in cirrhosis

Christos K. Triantos, Dimitrios Samonakis, Ulrich Thalheimer, Evangelos Cholongitas, Marco Senzolo, Laura Marelli, Gioacchino Leandro, David Patch, Andrew K. Burroughs

Research output: Contribution to journalArticle

Abstract

Objectives: Renal failure is common in cirrhosis frequently due to hepatorenal syndrome (HRS). Terlipressin and albumin improve renal function with a trend to prolong survival in HRS, but prognostic factors with therapy have been poorly studied. Methods: Forty-five cirrhotics seen consecutively in a single centre with renal failure defined as oliguria/anuria and/or rising creatinine and no response to volume loading, without intrinsic renal disease, sepsis, gastrointestinal bleeding [median Child-Pugh score 12(8-14)/Model for End-Stage Liver Disease 29(10-40)], had intravenous terlipressin and albumin and were audited retrospectively classified into three groups: group 1 HRS type 1 (15), group 2 HRS type 2 (11) and group 3(19): not fulfilling HRS 1 or 2 criteria. Baseline median creatinine was 1.7 (0.9-5.46)mg/dl and 30 (67%) had creatinine greater than 1.5mg/dl. All 45 patients had initial colloid/albumin and 31 continued terlipressin (2-4mg/day) for a median 8 (2-76) days. Results: Improvement in serum creatinine occurred in 23 (51%) [(1.3mg/dl (0.6-3.9)] compared with baseline [1.7mg/dl (0.92-3.75)] (P

Original languageEnglish
Pages (from-to)481-486
Number of pages6
JournalEuropean Journal of Gastroenterology and Hepatology
Volume22
Issue number4
DOIs
Publication statusPublished - Apr 2010

Fingerprint

Hepatorenal Syndrome
Renal Insufficiency
Fibrosis
Creatinine
Albumins
Oliguria
Anuria
Kidney
Therapeutics
End Stage Liver Disease
Gastrointestinal Diseases
Colloids
Sepsis
terlipressin
Hemorrhage
Survival
Serum

Keywords

  • Cirrhosis
  • Hepatorenal syndrome
  • Terlipressin

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

Triantos, C. K., Samonakis, D., Thalheimer, U., Cholongitas, E., Senzolo, M., Marelli, L., ... Burroughs, A. K. (2010). Terlipressin therapy for renal failure in cirrhosis. European Journal of Gastroenterology and Hepatology, 22(4), 481-486. https://doi.org/10.1097/MEG.0b013e3283345524

Terlipressin therapy for renal failure in cirrhosis. / Triantos, Christos K.; Samonakis, Dimitrios; Thalheimer, Ulrich; Cholongitas, Evangelos; Senzolo, Marco; Marelli, Laura; Leandro, Gioacchino; Patch, David; Burroughs, Andrew K.

In: European Journal of Gastroenterology and Hepatology, Vol. 22, No. 4, 04.2010, p. 481-486.

Research output: Contribution to journalArticle

Triantos, CK, Samonakis, D, Thalheimer, U, Cholongitas, E, Senzolo, M, Marelli, L, Leandro, G, Patch, D & Burroughs, AK 2010, 'Terlipressin therapy for renal failure in cirrhosis', European Journal of Gastroenterology and Hepatology, vol. 22, no. 4, pp. 481-486. https://doi.org/10.1097/MEG.0b013e3283345524
Triantos CK, Samonakis D, Thalheimer U, Cholongitas E, Senzolo M, Marelli L et al. Terlipressin therapy for renal failure in cirrhosis. European Journal of Gastroenterology and Hepatology. 2010 Apr;22(4):481-486. https://doi.org/10.1097/MEG.0b013e3283345524
Triantos, Christos K. ; Samonakis, Dimitrios ; Thalheimer, Ulrich ; Cholongitas, Evangelos ; Senzolo, Marco ; Marelli, Laura ; Leandro, Gioacchino ; Patch, David ; Burroughs, Andrew K. / Terlipressin therapy for renal failure in cirrhosis. In: European Journal of Gastroenterology and Hepatology. 2010 ; Vol. 22, No. 4. pp. 481-486.
@article{107f2fa146e54d9a95b04f1bd0d30477,
title = "Terlipressin therapy for renal failure in cirrhosis",
abstract = "Objectives: Renal failure is common in cirrhosis frequently due to hepatorenal syndrome (HRS). Terlipressin and albumin improve renal function with a trend to prolong survival in HRS, but prognostic factors with therapy have been poorly studied. Methods: Forty-five cirrhotics seen consecutively in a single centre with renal failure defined as oliguria/anuria and/or rising creatinine and no response to volume loading, without intrinsic renal disease, sepsis, gastrointestinal bleeding [median Child-Pugh score 12(8-14)/Model for End-Stage Liver Disease 29(10-40)], had intravenous terlipressin and albumin and were audited retrospectively classified into three groups: group 1 HRS type 1 (15), group 2 HRS type 2 (11) and group 3(19): not fulfilling HRS 1 or 2 criteria. Baseline median creatinine was 1.7 (0.9-5.46)mg/dl and 30 (67{\%}) had creatinine greater than 1.5mg/dl. All 45 patients had initial colloid/albumin and 31 continued terlipressin (2-4mg/day) for a median 8 (2-76) days. Results: Improvement in serum creatinine occurred in 23 (51{\%}) [(1.3mg/dl (0.6-3.9)] compared with baseline [1.7mg/dl (0.92-3.75)] (P",
keywords = "Cirrhosis, Hepatorenal syndrome, Terlipressin",
author = "Triantos, {Christos K.} and Dimitrios Samonakis and Ulrich Thalheimer and Evangelos Cholongitas and Marco Senzolo and Laura Marelli and Gioacchino Leandro and David Patch and Burroughs, {Andrew K.}",
year = "2010",
month = "4",
doi = "10.1097/MEG.0b013e3283345524",
language = "English",
volume = "22",
pages = "481--486",
journal = "European Journal of Gastroenterology and Hepatology",
issn = "0954-691X",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Terlipressin therapy for renal failure in cirrhosis

AU - Triantos, Christos K.

AU - Samonakis, Dimitrios

AU - Thalheimer, Ulrich

AU - Cholongitas, Evangelos

AU - Senzolo, Marco

AU - Marelli, Laura

AU - Leandro, Gioacchino

AU - Patch, David

AU - Burroughs, Andrew K.

PY - 2010/4

Y1 - 2010/4

N2 - Objectives: Renal failure is common in cirrhosis frequently due to hepatorenal syndrome (HRS). Terlipressin and albumin improve renal function with a trend to prolong survival in HRS, but prognostic factors with therapy have been poorly studied. Methods: Forty-five cirrhotics seen consecutively in a single centre with renal failure defined as oliguria/anuria and/or rising creatinine and no response to volume loading, without intrinsic renal disease, sepsis, gastrointestinal bleeding [median Child-Pugh score 12(8-14)/Model for End-Stage Liver Disease 29(10-40)], had intravenous terlipressin and albumin and were audited retrospectively classified into three groups: group 1 HRS type 1 (15), group 2 HRS type 2 (11) and group 3(19): not fulfilling HRS 1 or 2 criteria. Baseline median creatinine was 1.7 (0.9-5.46)mg/dl and 30 (67%) had creatinine greater than 1.5mg/dl. All 45 patients had initial colloid/albumin and 31 continued terlipressin (2-4mg/day) for a median 8 (2-76) days. Results: Improvement in serum creatinine occurred in 23 (51%) [(1.3mg/dl (0.6-3.9)] compared with baseline [1.7mg/dl (0.92-3.75)] (P

AB - Objectives: Renal failure is common in cirrhosis frequently due to hepatorenal syndrome (HRS). Terlipressin and albumin improve renal function with a trend to prolong survival in HRS, but prognostic factors with therapy have been poorly studied. Methods: Forty-five cirrhotics seen consecutively in a single centre with renal failure defined as oliguria/anuria and/or rising creatinine and no response to volume loading, without intrinsic renal disease, sepsis, gastrointestinal bleeding [median Child-Pugh score 12(8-14)/Model for End-Stage Liver Disease 29(10-40)], had intravenous terlipressin and albumin and were audited retrospectively classified into three groups: group 1 HRS type 1 (15), group 2 HRS type 2 (11) and group 3(19): not fulfilling HRS 1 or 2 criteria. Baseline median creatinine was 1.7 (0.9-5.46)mg/dl and 30 (67%) had creatinine greater than 1.5mg/dl. All 45 patients had initial colloid/albumin and 31 continued terlipressin (2-4mg/day) for a median 8 (2-76) days. Results: Improvement in serum creatinine occurred in 23 (51%) [(1.3mg/dl (0.6-3.9)] compared with baseline [1.7mg/dl (0.92-3.75)] (P

KW - Cirrhosis

KW - Hepatorenal syndrome

KW - Terlipressin

UR - http://www.scopus.com/inward/record.url?scp=77949456635&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949456635&partnerID=8YFLogxK

U2 - 10.1097/MEG.0b013e3283345524

DO - 10.1097/MEG.0b013e3283345524

M3 - Article

C2 - 19952764

AN - SCOPUS:77949456635

VL - 22

SP - 481

EP - 486

JO - European Journal of Gastroenterology and Hepatology

JF - European Journal of Gastroenterology and Hepatology

SN - 0954-691X

IS - 4

ER -